Brean Capital reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), and raised the price target to $55.00 (from $45.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill LynchSeptember 23, 2015 1:25 PM Pre-Open Stock 09/23: (SGNL) (HRTX) (BMR) Higher; (OGXI) (more..)September 23, 2015 9:24 AM Leerink Boosts PT on Heron Therapeutics (HRTX) to $57 Following HTX-011 Phase 2 Top-Line ResultsSeptember 23, 2015 6:50 AM Heron Therapeutics (HRTX) PT Lifted to $58 at Jefferies Following Positive DataSeptember 23, 2015 6:46 AM Market Wrap: Commodities Weigh on Markets; Home Price Gains Outpaced in July; Splitsville for AshlandSeptember 22, 2015 5:23 PM Heron Therapeutics (HRTX) Announces HTX-011 Phase 2 Met Primary, Secondary Endpoints in Post-Operative PainSeptember 22, 2015 4:07 PM Heron Therapeutics (HRTX) Announces Top-Line Results From Phase 2 Study of HTX-011 in Post-Operative PainSeptember 22, 2015 4:06 PM Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative PainSeptember 22, 2015 4:05 PM Heron Therapeutics (HRTX) to Present SUSTOL Data as CINV Prevention at ASCO 2015 Breast Cancer SymposiumSeptember 22, 2015 8:06 AM Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL® at ASCO Breast Cancer SymposiumSeptember 22, 2015 8:01 AM